Marcus-Hillert Schultze-Mosgau

Title: Marcus-Hillert Schultze-Mosgau: Innovator in Pharmaceutical Composition

Introduction

Marcus-Hillert Schultze-Mosgau is a notable inventor based in Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative dosage forms. His work focuses on addressing critical health issues related to gynaecological diseases.

Latest Patents

Marcus-Hillert Schultze-Mosgau holds a patent for a pharmaceutical composition titled "Progesterone Receptor Antagonist Dosage Form." This invention involves a composition that includes a progesterone receptor antagonist, specifically (11 ß,17ß)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one, at a dosage of about 0.5 to 5 mg, with a particular emphasis on 2 mg. The composition is intended for the treatment and prophylaxis of gynaecological diseases, such as fibroids of the uterus, endometriosis, and excessive menstrual bleeds.

Career Highlights

Marcus-Hillert Schultze-Mosgau is currently associated with Bayer Pharma Aktiengesellschaft, a leading company in the pharmaceutical industry. His role involves research and development, focusing on innovative solutions for women's health. Despite having no patents listed under his name, his contributions to the field are noteworthy.

Collaborations

Throughout his career, Marcus-Hillert Schultze-Mosgau has collaborated with esteemed colleagues, including Barbara Schutt and Andreas Kaiser. These partnerships have fostered a collaborative environment that enhances the development of effective pharmaceutical solutions.

Conclusion

Marcus-Hillert Schultze-Mosgau is a dedicated inventor whose work in pharmaceutical compositions has the potential to significantly impact women's health. His innovative approach to addressing gynaecological diseases showcases the importance of research and development in the pharmaceutical industry.